Windlas BiotechNSE:WINDLAS -0.51%90 Return-on-Tangible-Equity is 11.14% as of Mar. 2026, which is 12% below its 10-year median of 12.63. GuruFocus rates NSE:WINDLAS with a GF Score™ of 90/100 and a GF Value™ of ₹940.03 (Fairly Valued). The stock has 1 warning sign investors should review. Among 897 Drug Manufacturers companies, Windlas Biotech ranks better than 64.1% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Windlas Biotech's annualized net income for the quarter that ended in Mar. 2026 was ₹640 Mil. Windlas Biotech's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹5,739 Mil. Therefore, Windlas Biotech's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 11.14%.
The historical rank and industry rank for Windlas Biotech's Return-on-Tangible-Equity or its related term are showing as below:
NSE:WINDLAS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.77 Med: 12.63 Max: 33.04
Current: 12.46
During the past 8 years, Windlas Biotech's highest Return-on-Tangible-Equity was 33.04%. The lowest was 7.77%. And the median was 12.63%.
NSE:WINDLAS's Return-on-Tangible-Equity is ranked better than 64.1% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs NSE:WINDLAS: 12.46
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Windlas Biotech Return-on-Tangible-Equity Related Terms
Windlas Biotech Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:WINDLAS vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.14% mean?
Windlas Biotech (NSE:WINDLAS) has a Return-on-Tangible-Equity of 11.14% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Windlas Biotech and its competitors. This is 12% below median its historical median of 12.63. Over the past decade, Windlas Biotech's Return-on-Tangible-Equity has ranged from 7.77 to 33.04. According to the industry distribution chart, Windlas Biotech ranks #322 out of 897 companies in the Drug Manufacturers industry, placing it in the top 35.9%.
Is Windlas Biotech's Return-on-Tangible-Equity too high?
Windlas Biotech's current Return-on-Tangible-Equity of 11.14% is 12% below median its 10-year median of 12.63. Over the past 10 years, this metric has ranged from a low of 7.77 to a high of 33.04. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Windlas Biotech's value of 11.14% is 41% above this industry median. Based on the distribution chart, Windlas Biotech ranks #322 out of 897 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Windlas Biotech has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #322 out of 897 companies for Return-on-Tangible-Equity. This puts Windlas Biotech in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Windlas Biotech's value of 11.14% is 41% above this benchmark. Historically, Windlas Biotech's own Return-on-Tangible-Equity has ranged from 7.77 to 33.04 over the past decade. While the company's 10-year median is 12.63 vs. the industry median of 7.90, Windlas Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windlas Biotech's current Return-on-Tangible-Equity of 11.14% is 41% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current Return-on-Tangible-Equity is 11.14%, which is 12% below median its own 10-year median of 12.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹940.03, compared to a current price of ₹853.95 — trading 9.2% below its estimated fair value. The current Return-on-Tangible-Equity is 11.14%, which is 12% below median its 10-year median of 12.63 and 41% above the Drug Manufacturers industry median of 7.90. Windlas Biotech's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Return-on-Tangible-Equity is 11.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹853.95 is trading 9.2% below its estimated GF Value™ of ₹940.03.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
Return-on-Tangible-Equity: 11.14% (12% below median its 10-year median of 12.63)
GF Value™: ₹940.03 vs. price of ₹853.95 (9.2% below fair value)
Industry Position: 41% above the Drug Manufacturers median (#322 of 897)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
90GF Score
Get the complete analysis for NSE:WINDLAS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
